The impact of epigenetic chemical probes: expanding targeting modalities and disease understanding
Small-molecule chemical modulators (chemical probes) targeting epigenetic regulators are essential tools for research by enabling precise temporal control over chromatin dynamics. Over the past two decades, large international efforts have produced hundreds of validated and openly accessible chemical probes. While the field was initially driven by occupancy-based catalytic inhibitors, there has been a recent shift toward context-dependent target engagement and induced proximity strategies. By repurposing established chemical ligands, next-generation heterobifunctional modalities (e.g., PROTACs and RIPTACs) can drive targeted protein degradation or disrupt multi-protein complexes to achieve deeper functional effects. In the present review, we discuss the evolution of epigenetic chemical probes, the emergence of induced proximity strategies, and the importance of recognizing that different targeting modalities for a given protein may yield distinct biological outcomes. Collectively, the history of epigenetic probes provides a foundation for Target 2035, an international initiative led by the Structural Genomics Consortium aimed at developing pharmacological modulators across the human proteome.
Authors
- C.H. Arrowsmith (ORCID: https://orcid.org/0000-0002-4971-3250)
- Dalia Baršytė-Lovejoy (ORCID: https://orcid.org/0000-0002-6560-9621)
- Philip Barbulescu (ORCID: https://orcid.org/0000-0002-5070-5661)
Institutions
- University Health Network (CA)
- University of Toronto (CA)
- Princess Margaret Cancer Centre (CA)
- Structural Genomics Consortium (CA)
Publication Details
- Journal
- Essays in Biochemistry
- Published
- 2026-11-18
- DOI
- https://doi.org/10.1042/ebc20260009
- Primary Topic
- Protein Degradation and Inhibitors
- Type
- article
- Field-Weighted Citation Impact
- 0.00